Literature DB >> 23650254

Haemodialysis before emergency surgery in a patient treated with dabigatran.

P Esnault1, P E Gaillard, J Cotte, P J Cungi, J Beaume, B Prunet.   

Abstract

Novel oral anticoagulants (NOAs) which directly inhibit thrombin (dabigatran) or factor Xa (rivaroxaban and apixaban) have recently been developed. We report the first case of perioperative management of a patient treated with dabigatran requiring haemodialysis before emergency surgery. A 62-yr-old woman visited the emergency department for a left bi-malleolar ankle fracture; she had a past medical history of severe ischaemic cardiomyopathy, alcoholic cirrhosis Child B, and moderate chronic renal insufficiency. The patient was treated with dabigatran for a left ventricular aneurysm with thrombus. Cutaneous manifestation of a voluminous haematoma required emergency surgery. Blood tests revealed dabigatran anticoagulant activity of 123 ng ml(-1) (therapeutic values: 85-200 ng ml(-1)), activated partial thromboplastin time of 63 s, and a prothrombin ratio of 68%, indicating that dabigatran disturbed coagulation. We decided to perform emergency haemodialysis before surgery. After 2 h, the anticoagulant activity of dabigatran was 11 ng ml(-1), allowing surgery. Surgery proceeded without any problems and the postoperative period was unremarkable. This case highlights the difficulties for the anaesthesiologist regarding emergency perioperative management of patients treated with NOAs and confirms the efficacy of haemodialysis in cases of dabigatran treatment. NOAs should be prescribed with caution, especially for patients with renal or hepatic disease, at least as long as no antagonist is available. In cases of deferred operative urgency in haemodynamically stable patients treated with dabigatran, haemodialysis should be considered to reverse dabigatran's anticoagulant effects.

Entities:  

Keywords:  dabigatran; haemodialysis; surgery

Mesh:

Substances:

Year:  2013        PMID: 23650254     DOI: 10.1093/bja/aet160

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  5 in total

Review 1.  Enhanced elimination of dabigatran through extracorporeal methods.

Authors:  Nadia I Awad; Luigi Brunetti; David N Juurlink
Journal:  J Med Toxicol       Date:  2015-03

2.  Management of gastrointestinal bleeding in patients anticoagulated with dabigatran compared with warfarin: a retrospective, comparative case review.

Authors:  Wuttiporn Manatsathit; Hussein Al-Hamid; Pornchai Leelasinjaroen; Usman Hashmi; Peter A McCullough
Journal:  Cardiovasc Diagn Ther       Date:  2014-06

3.  Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit.

Authors:  Guillaume Claisse; Xavier Delavenne; Ingrid Masson; Nicolas Maillard; Eric Alamartine; Christophe Mariat
Journal:  Clin Kidney J       Date:  2015-01-24

4.  Impaired renal function and abnormal level of ferritin are independent risk factors of left ventricular aneurysm after acute myocardial infarction: A hospital-based case-control study.

Authors:  Yunfei Feng; Qiqi Wang; Guoping Chen; Dan Ye; Weiwei Xu
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

5.  Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model.

Authors:  Oliver Grottke; Joanne van Ryn; Henri M H Spronk; Rolf Rossaint
Journal:  Crit Care       Date:  2014-02-05       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.